Metabolic Profiling of the Synthetic Cannabinoid APP-CHMINACA (PX-3) As Studied by in Vitro and in Vivo Models

Overview

Journal Forensic Toxicol

Specialties Forensic Sciences
Toxicology

Date 2024 Nov 22

PMID 39576558

Authors

Cristian Camuto

Fabio De-Giorgio

Giorgia Corli

Sabrine Bilel

Monica Mazzarino

Matteo Marti

Francesco Botre

Affiliations

Soon will be listed here.

Abstract

Purpose: The metabolic pathways of APP-CHMINACA were characterized to select the markers of intake for implementation into analytical assays used by the clinical and forensic communities. We have combined the evidences obtained by both in vitro experiments and administration studies on mice.

Methods: APP-CHMINACA was incubated with either human or mouse liver microsomes. Urine and blood samples were collected at different time points from mice after injection of a 3 mg/kg dose of the test compound. Samples were analyzed using liquid chromatography-tandem mass spectrometry.

Results: The in vitro studies allowed to isolate eight different metabolic reactions, formed by two metabolic routes, with no differences between human and mouse liver microsomes. The main biotransformation route involved the hydrolysis of the distal amide group and the subsequent hydroxylation on the cyclohexyl-methyl ring. The second route involved multiple hydroxylation of the parent compound, followed by reduction to generate minor metabolites. In blood samples, the most abundant substances identified were APP-CHMINACA unchanged and the metabolites formed by the hydrolysis of the distal amide together with its hydroxylated products. In urine samples, four metabolites formed following the hydroxylation of the distal amide hydrolysis metabolite were detected as the most abundant and long-term metabolites.

Conclusions: The outcomes of our study showed that the most suitable markers to detect the intake of APP-CHMINACA in blood and urine samples in the framework of toxicological, clinical and forensic investigations were the metabolite formed by the hydrolysis of the distal amide and its hydroxylated products.

References

Kaneko S . Motor vehicle collisions caused by the 'super-strength' synthetic cannabinoids, MAM-2201, 5F-PB-22, 5F-AB-PINACA, 5F-AMB and 5F-ADB in Japan experienced from 2012 to 2014. Forensic Toxicol. 2017; 35(2):244-251. PMC: 5486620. DOI: 10.1007/s11419-017-0369-6. View

Presley B, Logan B, Jansen-Varnum S . In Vitro Metabolic Profile Elucidation of Synthetic Cannabinoid APP-CHMINACA (PX-3). J Anal Toxicol. 2019; 44(3):226-236. DOI: 10.1093/jat/bkz086. View

Mustata C, Torrens M, Pardo R, Perez C, Farre M . [Spice drugs: cannabinoids as a new designer drugs]. Adicciones. 2009; 21(3):181-6. View

Hudson S, Ramsey J . The emergence and analysis of synthetic cannabinoids. Drug Test Anal. 2011; 3(7-8):466-78. DOI: 10.1002/dta.268. View

Gurney S, Scott K, Kacinko S, Presley B, Logan B . Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs. Forensic Sci Rev. 2015; 26(1):53-78. View

Potts A, Cano C, Thomas S, Hill S . Synthetic cannabinoid receptor agonists: classification and nomenclature. Clin Toxicol (Phila). 2019; 58(2):82-98. DOI: 10.1080/15563650.2019.1661425. View

Kakehashi H, Shima N, Ishikawa A, Nitta A, Asai R, Wada M . Effects of lipophilicity and functional groups of synthetic cannabinoids on their blood concentrations and urinary excretion. Forensic Sci Int. 2020; 307:110106. DOI: 10.1016/j.forsciint.2019.110106. View

Diao X, Huestis M . New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. Front Chem. 2019; 7:109. PMC: 6409358. DOI: 10.3389/fchem.2019.00109. View

Botre F . Drugs of abuse and abuse of drugs in sportsmen: the role of in vitro models to study effects and mechanisms. Toxicol In Vitro. 2003; 17(5-6):509-13. DOI: 10.1016/s0887-2333(03)00120-6. View

10.

Mazzarino M, Rizzato N, Stacchini C, de la Torre X, Botre F . A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009. Drug Test Anal. 2018; 10(11-12):1670-1681. DOI: 10.1002/dta.2538. View

11.

Camuto C, Guglielmelli A, De-Giorgio F, de la Torre X, Mazzarino M, Marti M . In vitro metabolic profile of mexedrone, a mephedrone analog, studied by high- and low-resolution mass spectrometry. Drug Test Anal. 2021; 14(2):269-276. PMC: 9298855. DOI: 10.1002/dta.3179. View

12.

Mazzarino M, Camuto C, Comunita F, de la Torre X, Stacchini C, Botre F . Application of liquid chromatography coupled to data-independent acquisition mass spectrometry for the metabolic profiling of N-ethyl heptedrone. J Chromatogr B Analyt Technol Biomed Life Sci. 2021; 1185:122989. DOI: 10.1016/j.jchromb.2021.122989. View

13.

Canazza I, Ossato A, Vincenzi F, Gregori A, Di Rosa F, Nigro F . Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. Hum Psychopharmacol. 2017; 32(3). DOI: 10.1002/hup.2601. View

14.

Seely K, Lapoint J, Moran J, Fattore L . Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 39(2):234-43. PMC: 3936256. DOI: 10.1016/j.pnpbp.2012.04.017. View

15.

Doi T, Tagami T, Takeda A, Asada A, Sawabe Y . Evaluation of carboxamide-type synthetic cannabinoids as CB/CB receptor agonists: difference between the enantiomers. Forensic Toxicol. 2018; 36(1):51-60. PMC: 5754384. DOI: 10.1007/s11419-017-0378-5. View

16.

King L, Kicman A . A brief history of 'new psychoactive substances'. Drug Test Anal. 2011; 3(7-8):401-3. DOI: 10.1002/dta.319. View

17.

Mazzarino M, Buccilli V, de la Torre X, Fiacco I, Palermo A, Ughi D . Characterization of the phase I and phase II metabolic profile of tolvaptan by in vitro studies and liquid chromatography-mass spectrometry profiling: Relevance to doping control analysis. J Pharm Biomed Anal. 2017; 145:555-568. DOI: 10.1016/j.jpba.2017.06.054. View

18.

Martinotti G, Santacroce R, Papanti D, Elgharably Y, Prilutskaya M, Corazza O . Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset. CNS Neurol Disord Drug Targets. 2017; 16(5):567-575. DOI: 10.2174/1871527316666170413101839. View

19.

Schoeder C, Hess C, Madea B, Meiler J, Muller C . Pharmacological evaluation of new constituents of "Spice": synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. Forensic Toxicol. 2018; 36(2):385-403. PMC: 6002460. DOI: 10.1007/s11419-018-0415-z. View

20.

Mazzarino M, Biava M, de la Torre X, Fiacco I, Botre F . Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies. Anal Bioanal Chem. 2013; 405(16):5467-87. DOI: 10.1007/s00216-013-6961-7. View